Advanced Filters
noise

St. Louis, Missouri Clinical Trials

A listing of St. Louis, Missouri clinical trials actively recruiting patient volunteers.

Found 764 clinical trials
Y Yvonne Taul

MC1R-targeted Alpha-particle Therapy Trial in Adults With Advanced Melanoma

In this first-in human, phase I/IIa study, the safety and efficacy of [212Pb]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated in patients with unresectable and metastatic melanoma.

18 - 90 years of age All Phase 1/2
K Kathryn S Sutton, MD

Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors

The primary objective of this study is to improve the 2-year progression-free survival in children with high-risk solid tumors who are administered a maintenance regimen with continuous sirolimus administered on a backbone of metronomic chemotherapy following the completion of "standard" therapy, as compared to high-risk solid tumor patients treated with …

1 - 30 years of age All Phase 2
S Steven Attia, DO

Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)

The present study is an open-label, randomized, controlled, two-arm multi-center study of the efficacy of L19TNF treatment in combination with doxorubicin versus doxorubicin alone in metastatic leiomyosarcoma patients.

16 - 100 years of age All Phase 2
A Aaron White

Neuroblastoma Maintenance Therapy Trial

Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 …

1 - 30 years of age All Phase 2
M Meagan Jacoby, M.D., Ph.D.

Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS

This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for patients with the diagnosis of myelodysplastic syndrome (MDS).

18 years of age All Phase N/A
L Lulu Huang

Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF)

The aim of this study is to assess the safety and preliminary efficacy of treatment with EXE-346, a live biotherapeutic, which may reduce bowel movement frequency in patients with an ileal pouch-anal anastomosis (IPAA) and lead to a higher quality of life.

18 - 65 years of age All Phase 1/2

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order …

18 years of age Female Phase 1/2
C Cristina Toedebusch, BS

Sleep Trial to Prevent Alzheimer's Disease

The purpose of this study is to determine if treatment with the sleep aid suvorexant can decrease the rate of amyloid-β (Aβ) accumulation in the brain.

65 years of age All Phase 2

ARX517 in Subjects With Metastatic Castration-Resistant Prostate Cancer

This is a phase 1 study to assess the safety and tolerability of ARX517 in adult subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC).

18 years of age Male Phase 1

Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA

The purpose of this study is to evaluate the safety and efficacy of narsoplimab in pediatric patients with thrombotic microangiopathies (TMA) following hematopoietic stem cell transplant (HSCT).

28 - 17 years of age All Phase 2

Simplify language using AI